Loading...
Dernières publications
-
Luce Barbat Du Closel, Nathalie Bonello-Palot, Yann Pereon, Andoni Echaniz-Laguna, Jean Philippe Camdessanche, et al.. Clinical and electrophysiological characteristics of women with X-linked Charcot-Marie-Tooth disease. European Journal of Neurology, 2023, 30 (10), pp.3265-3276. ⟨10.1111/ene.15937⟩. ⟨hal-04254200⟩
-
-
Joe-Elie Salem, Marie Bretagne, Baptiste Abbar, Sarah Leonard-Louis, Stéphane Ederhy, et al.. Abatacept/Ruxolitinib and Screening for Concomitant Respiratory Muscle Failure to Mitigate Fatality of Immune-Checkpoint Inhibitor Myocarditis. Cancer Discovery, 2023, 13 (5), pp.1100-1115. ⟨10.1158/2159-8290.CD-22-1180⟩. ⟨hal-04578810⟩
-
-
Corinna Preuße, Barbara Paesler, Christopher Nelke, Derya Cengiz, Thomas Müntefering, et al.. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathologica, 2022, 144 (2), pp.353-372. ⟨10.1007/s00401-022-02438-z⟩. ⟨hal-03830925⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-03832478⟩
-
Lee Nguyen, Marie Bretagne, Jennifer Arrondeau, Noel Zahr, Stephane Ederhy, et al.. Reversal of immune-checkpoint inhibitor fulminant myocarditis using personalized-dose-adjusted abatacept and ruxolitinib: proof of concept. Journal for Immunotherapy of Cancer, 2022, 10 (4), pp.e004699. ⟨10.1136/jitc-2022-004699⟩. ⟨hal-04002766⟩
-
-
Stéphane Ederhy, Perrine Devos, Bruno Pinna, Elisa Funck-Brentano, Baptiste Abbar, et al.. 8 F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography imaging for the diagnosis of immune checkpoint inhibitors associated myocarditis. Archives of cardiovascular diseases, 2022, ⟨10.1016/j.acvd.2021.12.001⟩. ⟨hal-03561783⟩
-
Chiffres clés
123
Publications avec texte intégral
Open Access
53 %
Mots clés
Autoimmune diseases
Aldosterone
Biomarqueurs
Anti-IgE IgG
Acid-alpha-glucosidase
Mass cytometry
Anti‐mitochondrial antibodies
Immune checkpoint inhibitors
Polymyositis
Muscle
Anti-MDA5 autoantibodies
Anémie hémolytique
IBM
Adult
Autoantibody
Antiphospholipid syndrome
Biomarker
Male
Humans
Dermatomyositis
Fabry disease
Biomarkers
AAV antibody
Autoimmunity
Inflammatory myopathy
Anticorps anti-agalsidase
AAV
Agalsidase
Abnormal movement
Active
Adolescence
Female
Dependovirus/genetics/immunology
Auto‐antibodies
Anti-synthetase syndrome
Myocarditis
Analyses multidimensionnelles
Anti-Mi2
Inclusion body myositis
Anti-drug antibodies
Skeletal muscle
Aldostérone
Cardio-oncology
Case reports
IMNM
Animals
Systems biology
Machine learning
Acute Kidney Injury/epidemiology/etiology
Deep immune profiling
Antisynthetase syndrome
Antisynthetase
Immunotherapy
COVID-19
Cytokines
Adjudication
DM
Amyotrophy
Antibodies
AAV vectors
Pharmacology
Middle Aged
Auto-immunité
Anti-agalsidase antibodies
Antibody responses
Myositis and muscle disease
Autoantibodies
Adeno-associated virus
Prognosis
Biopsy
Auto-antibodies
Interstitial lung disease
Sphingosine-1-phosphate
Gene therapy
Anticorps spécifique des myosites
Inflammation
Multidisciplinarity
Lysosomal storage diseases
Amyotrophic lateral sclerosis
Outcome measures
Aged
Bioelectrical impedance analysis
AAV humoral immunity
Anti-interleukin-6
Arthritis
Interferon
Adeno-associated virus vector
Assisted communication devices
Inborn errors of metabolism
B-lymphocyte
Adeno-associated vector
Idiopathic inflammatory myopathies
Data integration
Myositis
Myopathy
Cancer
AAV vector
B cell homeostasis
Adverse drug reactions
Antisynthétase